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To the Editor, 
Factor  V  Leiden  (FVL)  mutation  (G1691A)  is  a 
risk factor for the development of venous thrombo-
embolic disorders. Hereditary disorders that predis-
pose to thrombosis include antithrombin, protein C, 
and protein S deficiency, as well as such hereditary 
defects as Factor V G1691A (Leiden) (FVL) and pro-
thrombin G20210A mutation [1,2]. FVL causes acti-
vated protein C resistance and is the most common 
thrombophilic mutation worldwide [3,4]; however, 
to the best of our knowledge the frequency of FVL 
in Iraqi Turks has not been reported. 
Iraqi  Turks  currently  live  primarily  in  northern 
Iraq and are descendants of the Oghuz Turks that 
originated in Central Asia. The study group included 
84 unrelated Iraqi Turks from northern Iraq; 40 from 
Kirkuk,  20  from  Mosul,  10  from  Arbil,  10  from 
Baghdad, and 4 from the Diala and Tikrit regions. 
Following the receipt of informed consent from all 
the participants, blood samples were collected into 
tubes containing EDTA and transferred To the labo-
ratory, and then DNA was extracted from peripheral 
blood  leukocytes  according  to  the  phenol-chloro-
form  method.  The  prevalence  of  FVL  was  deter-
mined using real-time PCR (RT-PCR), as previously 
described [5]. In all, 4 (4.8%) of the 84 participants 
were diagnosed as FVL carriers and the frequency 
of  FVL  was  0.0238%  among  Turks  living  in  Iraq. 
Several  studies  on  FVL  mutation  in  the  Turkish 
population  have  been  published  and  the  preva-
lences reported ranged from 4% to 12.2% [6]. The 
prevalence  of  FVL  among  Turkish  Cypriots  was 
reported as 12.2% versus 7.9% in Turkey [6,7]. The 
prevalence of FVL is 3%-10% in Europeans, but FVL 
mutation is rare in East and Southeast Asians [3,4]. 
The present study’s results show that the preva-
lence of FVL in Iraqi Turks is similar to that in the 
general Caucasian population.
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